NeuroOne Q1 net loss $1.4M; guides FY26 product revenue at least $10.5M

NEUROONE MEDICAL TECHNOLOGIES Corp

2026-Q1 EPS reported -$0.03 vs consensus -$0.23 ▲ beat (+87.0%)

Q1 product revenue $2.9M (down 12% YoY, but up 5.5% sequentially from Q4 FY25).
Net loss $1.4M ($0.03/sh) vs net income $1.8M ($0.06/sh) in Q1 FY25 due to no license revenue.
Cash $3.6M as of Dec 31, 2025; funded through FY26 if milestones hit.
Completed 9 trigeminal neuralgia cases after FDA clearance; all patients reportedly pain free.
Expects FY26 product revenue of at least $10.5M, a 17% YoY increase from $9.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.